Everpar Advisors LLC Invests $890,000 in Danaher Co. (NYSE:DHR)

Everpar Advisors LLC bought a new stake in shares of Danaher Co. (NYSE:DHR) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,847 shares of the conglomerate’s stock, valued at approximately $890,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its position in Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Northern Trust Corp grew its stake in Danaher by 1.7% during the 3rd quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after purchasing an additional 134,905 shares during the last quarter. Flossbach Von Storch AG grew its stake in Danaher by 1.8% during the 4th quarter. Flossbach Von Storch AG now owns 4,601,351 shares of the conglomerate’s stock valued at $1,064,477,000 after purchasing an additional 82,672 shares during the last quarter. Fisher Asset Management LLC grew its stake in Danaher by 6.2% during the 4th quarter. Fisher Asset Management LLC now owns 4,227,108 shares of the conglomerate’s stock valued at $977,900,000 after purchasing an additional 248,140 shares during the last quarter. Finally, Invesco Ltd. grew its stake in Danaher by 13.2% during the 3rd quarter. Invesco Ltd. now owns 4,070,455 shares of the conglomerate’s stock valued at $1,009,880,000 after purchasing an additional 473,693 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders sold 103,984 shares of company stock valued at $25,997,094 over the last quarter. 10.90% of the stock is currently owned by insiders.

Danaher Price Performance

NYSE DHR traded up $0.82 during trading hours on Wednesday, reaching $249.58. The company’s stock had a trading volume of 1,471,344 shares, compared to its average volume of 2,730,175. The firm has a market capitalization of $184.86 billion, a price-to-earnings ratio of 42.30, a P/E/G ratio of 3.82 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The company’s 50-day moving average is $248.27 and its two-hundred day moving average is $233.19.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the firm posted $2.36 EPS. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. On average, equities analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s payout ratio is currently 18.31%.

Analysts Set New Price Targets

Several analysts have weighed in on the company. TD Cowen boosted their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. KeyCorp boosted their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Royal Bank of Canada upped their target price on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Barclays upped their target price on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Finally, Bank of America upped their target price on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $267.31.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.